Patents Examined by Thomas G. Wiseman
  • Patent number: 4792522
    Abstract: A novel complex designated herein as rigolettone complex is produced by fermentation of Streptomyces aburaviensis strain C-38,242 (ATCC 39290). The complex and its purified bioactive components, jildamycin and mantuamycin, exhibit antitumor activity in mouse tumor systems.
    Type: Grant
    Filed: August 22, 1985
    Date of Patent: December 20, 1988
    Assignee: Bristol-Myers Company
    Inventors: Donald E. Nettleton, Jr., Stanley W. Bray, James A. Bush, William T. Bradner
  • Patent number: 4791059
    Abstract: This invention relates to a process for preparation of a novel lipase. The process is characterized by culturing a microorganism belonging to Staphylococcus capitis and capable of producing lipase in a culture medium to accumulate lipase in the cultured broth and recovering the lipase from the broth. Since the pH of this lipase is in a slightly alkali region and the lipase substantially completely converts glyceride to fatty acids and glycerin, it is useful for the economic preparation of fatty acids by the hydrolysis of fats or oils.
    Type: Grant
    Filed: March 17, 1986
    Date of Patent: December 13, 1988
    Assignee: Suntory Limited
    Inventors: Masahiro Nakao, Sumio Asami, Takaharu Tanaka, Kyoichi Ogura, Teruo Amachi, Hajime Yoshizumi, Hiroshi Ishigooka
  • Patent number: 4789633
    Abstract: Liposomes containing phosphatidylethanolamine, palmitoyl homocysteine or oleic acid or palmitic acid, fuse rapidly when the pH of the medium is reduced below 7. Liposome fusion was measured by (a) mixing of the liposomal lipids as shown by resonance energy transfer, (b) gel filtration and (c) electron microscopy. The presence of phosphatidylethanolamine or acid addition esters thereof in the liposomes greatly enhances fusion; whereas the presence of phosphatidylcholine inhibits fusion. During fusion of liposomes containing phosphatidylethanolamine:palmitoyl homocysteine (8:2), almost all of the encapsulate calcein is released. Inclusion of cholesterol (40%) in the liposomes substantially decreases leakage without impairing fusion. Those pH sensitive liposomes are fused to deliver biologically active molecules such as DNA, into living cells.
    Type: Grant
    Filed: April 19, 1984
    Date of Patent: December 6, 1988
    Assignee: University of Tennessee Research Corporation
    Inventors: Leaf Huang, Jerome Connor
  • Patent number: 4789658
    Abstract: An immunopropylactic and immunotherapeutic agent comprising human interleukin 2 of human cellular origin is disclosed along with a method of producing the agent.
    Type: Grant
    Filed: June 9, 1986
    Date of Patent: December 6, 1988
    Assignee: Ajinomoto Company, Incorporated
    Inventors: Ryota Yoshimoto, Nobukazu Kashima, Junji Hamuro, Koji Mitsugi
  • Patent number: 4788149
    Abstract: This invention relates to proteolytic enzymes with elastolytic properties from blood-sucking nematodes (hereinafter called HP enzymes). These enzymes are useful an anti-coagulants and as a means for dissolving fibrin clots. Because of their importance in the mechanism by which blood-sucking nematodes obtain nutrients from the host, HP enzymes would be an effective vaccine for prevention and treatment of these parasites. For the same reason, substances which inhibit HP enzymes would also be effective antithelminic agents.
    Type: Grant
    Filed: January 30, 1985
    Date of Patent: November 29, 1988
    Assignee: The Rockefeller University
    Inventors: Anthony Cerami, Peter Hotez
  • Patent number: 4788059
    Abstract: A vaccine for immunizing equines against strangles and a method of using the vaccine. The vaccine is made by isolating the causative organism Streptococcus equi (S. equi) from an abscess on a horse showing typical symptoms of strangles, and confirming the identity of the organism through standard biochemical techniques. The isolated S. equi is passed through a suitable growth medium (Todd-Hewitt broth) and two parts per million acriflavine hydrochloride is added. The acriflavine level is increased over a period of approximately eleven weeks to a concentration of about sixteen parts per million to yield an avirulent S. equi while retaining its antigenicity. The method of administering the vaccine consists of inoculating the horse intranasally with the attenuated S. equi.
    Type: Grant
    Filed: July 15, 1985
    Date of Patent: November 29, 1988
    Assignee: Coopers Animal Health, Inc.
    Inventor: Myron G. Usdin
  • Patent number: 4788148
    Abstract: A plasmid with stabilized inheritance containing at least one production gene introduced colinearly by gene technology. The plasmid is characterized by a nucleic acid fragment colinearly introduced therein and constituted by the gene for valyl-tRNA synthetase; cell containing such plasmid; and a process for preparing the plasmid.
    Type: Grant
    Filed: October 24, 1984
    Date of Patent: November 29, 1988
    Assignee: A C Biotechnics AB
    Inventors: Lars A. J. Nilsson, Stig G. Skogman
  • Patent number: 4786600
    Abstract: This invention concerns recombinant RNA molecules comprising a recognition sequence for the binding of an RNA-directed RNA polymerase, a sequence for the initiation of product strand synthesis and a heterologous sequence of interest inserted at a specific site in the internal region of the recombinant molecule. Such recombinant RNA molecules are capable of serving as a template for the synthesis of complementary single-stranded molecules by RNA-directed RNA polymerase. The product molecules so formed are also capable of serving as a template for the synthesis of additional copies of the original recombinant RNA molecule. In a preferred embodiment of the invention Q.beta. replicase is used as the RNA-directed RNA polymerase.
    Type: Grant
    Filed: May 25, 1984
    Date of Patent: November 22, 1988
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Fred R. Kramer, Eleanor A. Miele, Donald R. Mills
  • Patent number: 4784948
    Abstract: Methods and compositions are provided for the cloning and expression of Streptococcus pyogenes M protein genes, and, in particular, types 5, 6 and 24 genes in single-cell host organisms. The streptococcal M protein produced by the recombinant DNA techniques described herein may be formulated for use as immunogens in vaccines to protect against S. pyogenes infections. The gene for the M protein may further be employed as a molecular probe for the accurate identification of streptococci in infected body tissues and fluids.
    Type: Grant
    Filed: June 18, 1984
    Date of Patent: November 15, 1988
    Assignees: The Rockefeller University, Emory University
    Inventors: June R. Scott, Vincent A. Fischetti
  • Patent number: 4784949
    Abstract: A novel universal dominant selectable marker cassette is disclosed. The marker comprises the coding sequences for aminoglycoside phosphotransferase I (APH-I) which has been modified and truncated so as to render its use in recombinant vectors more convenient. The modified, truncated sequence (mtAPH-I) gene is capable, upon expression, of conferring resistance to a number of antibiotics on the host. One of these antibiotics, G418, is toxic to eucaryotic as well as procaryotic hosts. Also disclosed are methods of constructing fusion proteins having N-terminal sequences corresponding to a desired peptide sequence, and C-terminal sequences comprising the amino acids encoded by mtAPH-I.
    Type: Grant
    Filed: April 19, 1984
    Date of Patent: November 15, 1988
    Assignee: Cetus Corporation
    Inventors: David H. Gelfand, Frances C. Lawyer, Susanne Stoffel
  • Patent number: 4785080
    Abstract: A highly sensitive, immunoassay method for determining the amount of an analyte in a sample containing a known analyte in an unknown concentration is provided. Sample; a polypeptide-labeled analog of the analyte, an antibody specific for said analyte, a polypeptide partner capable of non-covalently binding with the polypeptide-labeled analyte to form a complex having catalytic activity, and a substrate capable of being converted to a reporter molecule by the catalytic activity of said complex are brought together in a medium. The polypeptide-labeled analyte analog is capable of competitively binding to the antibody and the polypeptide partner, the antibody inhibiting the formation of a catalytically active complex in the absence of analyte, and the concentration of the antibody, polypeptide partner and polypeptide-labeled analyte are such as to cause varying amounts of analyte to be directly related to the conversion of the substrate to the reporter molecule.
    Type: Grant
    Filed: August 29, 1985
    Date of Patent: November 15, 1988
    Assignee: Baker Instruments Corporation
    Inventors: Peter R. Farina, James R. Golke
  • Patent number: 4784952
    Abstract: Vectors suitable for effecting expression of lamB protein in a desired procaryotic host, and methods for their construction, are disclosed. Transformation with these vectors results in the ability of the procaryotic host to sustain infection by lambda phage.
    Type: Grant
    Filed: March 21, 1985
    Date of Patent: November 15, 1988
    Assignee: The Regents of the University of California
    Inventors: Robert A. Ludwig, Gert E. de Vries
  • Patent number: 4783410
    Abstract: A novel serine esterase produced by cytotoxic T lymphocytes is insolated and characterized. The protein appears to be membrane bound and has a reduced apparent molecular weight of about 28,000 daltons. Inhibition of the esterase correlates with inhibition of the cells' cytolytic activity. The serine esterase is useful in making antibody and as a target for the inhibition of cytolytic activity by T-lymphocytes, both in vivo and in vitro.
    Type: Grant
    Filed: June 28, 1985
    Date of Patent: November 8, 1988
    Assignee: Massachusetts Institute of Technology
    Inventors: Mark S. Pasternack, Herman N. Eisen
  • Patent number: 4783404
    Abstract: Yeasts of the genus cryptococcus, preferably of the species C. Laurentii, form, in the presence of aminoacids, an L-aminoacid oxidase which stereospecifically converts L-aminoacids and their derivatives into the corresponding .alpha.-ketoacids. The immobilized cells are advantageously used for this conversion, which can also be used to resolve racemates.
    Type: Grant
    Filed: September 14, 1984
    Date of Patent: November 8, 1988
    Assignee: Hoechst Aktiengesellschaft
    Inventors: Werner Aretz, Klaus Sauber
  • Patent number: 4783405
    Abstract: Recombinant DNA expression vectors for use in Bacillus and other host cells are disclosed. The vectors comprise the veg promoter sequence of Bacillus subtilis, a novel ribosome binding site-containing sequence and a sequence that codes for a functional polypeptide. The ribosome binding site-containing sequence is synthesized in accordance with conventional procedures while the veg promoter sequence can be obtained from E. coli K12 JA221/pMS480 (NRRL B-15258). Various sequences that codes for functional polypeptides and method for their expression in Bacillus are also disclosed.
    Type: Grant
    Filed: September 26, 1984
    Date of Patent: November 8, 1988
    Assignee: Eli Lilly and Company
    Inventors: Steven Kovacevic, James R. Miller, Hansen M. Hsiung
  • Patent number: 4783406
    Abstract: A method and compositions for the treatment of fireblight disease in plants are described. The compositions include a phage for Erwinia amylovora which produces fireblight and an enzyme produced by the phage which depolymerizes a polysaccharide produced by Erwinia amylovora which is the cause of the fireblight disease. Purified enzyme preparations are described.
    Type: Grant
    Filed: October 20, 1986
    Date of Patent: November 8, 1988
    Assignee: Microlife Technics, Inc.
    Inventors: Peter A. Vandenbergh, Anne K. Vidaver
  • Patent number: 4782023
    Abstract: An enzyme conjugate composition comprising an enzyme conjugate, a calcium salt and a polyethylene glycol is disclosed. The enzyme conjugate composition is effectively stabilized by the presence of the calcium salt and the polyethylene glycol.
    Type: Grant
    Filed: September 13, 1985
    Date of Patent: November 1, 1988
    Assignee: Abbott Laboratories
    Inventors: Mark A. Anawis, Roger E. Lindberg
  • Patent number: 4782021
    Abstract: This invention is a method of producing L-serine by causing glycine to react with formaldehyde by using the culture solution or the microbe cells of a microorganism belonging to the genus Escherichia, having the ability of producing serine hydroxymethyltransferase and not having the practical ability of producing L-serine from glycine alone or enzymatic matter obtained through the treatment of the above culture solution or microbe cells.In this invention, the yield of L-serine can be increased either by carrying out the reaction while maintaining aldehyde concentration at 20 mM or below or by using microbe cells of the aforementioned microorganism after they are caused to contact glycine.
    Type: Grant
    Filed: February 5, 1985
    Date of Patent: November 1, 1988
    Assignee: Mitsui Toatsu Chemicals, Inc.
    Inventors: Kenichi Ishiwata, Nobuyoshi Makiguichi, Hideki Kawashima, Tadashi Suzuki, Masami Imadegawa
  • Patent number: 4780416
    Abstract: The actinomycete "Actinomadura sp." designated in our culture collection as Strain No. G455-101 has been deposited with the American Type Culture Collection under the Accession Number ATCC No. 31491. The taxonomic description of this microorganism is presented in detail in the specification as are instructions for fermenting aqueous nutrient media with it to produce the BBM 928 antibiotic complex. The BBM 928 complex has utility as an antibacterial agent against gram-positive and acid fast bacteria and exhibits antitumor activity against experimental animal tumors.
    Type: Grant
    Filed: December 18, 1986
    Date of Patent: October 25, 1988
    Assignee: Bristol-Myers Company
    Inventors: Hideo Koshiyama, Fumihide Sakai, Hiroaki Ohkuma
  • Patent number: 4778756
    Abstract: A viral genomic DNA and fragments thereof which are complementary to genomic RNA of human leukemia virus and a recombinant DNA molecules containing the genomic DNA or fragments thereof. The genomic DNA and fragments thereof and the recombinant DNA molecules are useful for the diagnosis, prevention and therapy of human leukemia.
    Type: Grant
    Filed: October 5, 1987
    Date of Patent: October 18, 1988
    Assignee: Juridical Foundation, Japanese Foundation for Cancer Research
    Inventors: Mitsuaki Yoshida, Haruo Sugano